Bronchoalveolar Lavage Combined With High-throughput Sequencing Technology

Completed

• Conditions: Pneumonia

• Registration Number: NCT07005466
• Lead Sponsor: Nanfang Hospital, Southern Medical University

Brief Summary

High-throughput sequencing technology/Metagenomic next generation sequencing (mNGS) has extensive applications in fields such as whole-genome sequencing, transcriptome, gene expression regulation, and epigenetics. Because mNGS has the characteristics of large sequencing throughput, short time and high sensitivity, it can detect thousands of pathogens including bacteria, viruses, true bacteria and parasites, and is widely used in infectious diseases. In 2020, the "Expert Consensus on the Clinical Application of Metagenomic Second-Generation Sequencing Technology in Detecting Infectious Pathogens in China" proposed that for immunodeficient patients, mNGS can significantly increase the detection rate of pathogens and can be used as a first-line detection method. However, at present, there is no unified standard for the interpretation of mNGS results in the environment with bacteria in the respiratory tract, and there are not many studies on the efficacy of mNGS applied in the detection of bacteria and fungi. This study explored the clinical application value of mNGS in the pathogen detection of pneumonia in immunosuppressed hosts.

Detailed Description

Infection is the most common complication in immunosuppressed hosts, and lung infection is one of the leading causes of hospitalization and death in immunosuppressed hosts, and accurate pathogenetic diagnosis of pneumonia in immunosuppressed hosts remains challenging at present. Bronchoalveolar lavage is the standard method for sampling microorganisms in the lower respiratory tract, and with the progressive application of high-throughput sequencing (NGS) technology for pathogenetic testing and its success, we have clinically observed that bronchoalveolar lavage combined with NGS improves the rate of pathogenic diagnosis of pneumonia in the immunosuppressed host and benefits the patient. In this project, we plan to prospectively enroll patients with immunosuppressed host pneumonia and perform both bronchoalveolar lavage NGS and clinical conventional sputum culture, blood culture, TB-DNA test, fungal GM test, viral PCR test and other pathogenicity tests, and based on the above results, we will explore whether bronchoalveolar lavage in combination with NGS can increase the rate of pathogenic diagnosis of immunosuppressed host pneumonia and evaluate the effectiveness of the clinical value of NGS in serving as a tool for pneumonia detection and control and in optimizing antibiotic treatment strategies for pneumonia in immunosuppressed hosts.

This study compared the positive rate and accuracy rate of pathogen detection in immunosuppressive host pneumonia by mNGS and CMT, and explored the clinical value of bronchoalveolar lavage combined with high-throughput sequencing technology in the precise diagnosis of immunosuppressive host pneumonia. To increase the etiological diagnosis rate of pneumonia in immunosuppressed hosts, shorten the diagnosis time and improve its prognosis.

Study Timeline

• Study Start: 2019-01-20
• Primary Completion: 2024-12-30
• Study Completion: 2024-12-30
• Study First Submitted: 2025-05-26
• Status Verified: 2025-06
• Study First Submitted QC: 2025-06-04
• Last Update Submitted: 2025-06-04
• Study First Posted: 2025-06-05
• Last Update Posted: 2025-06-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sensitivity, specificity in pneumonia patients	2021.01-2024.12	Sensitivity: the ratio of the number of positive cases detected within the experimental group diagnosed with the disease by the gold standard.; Specificity: the ratio of the number of negative cases detected in the control group diagnosed as disease-free by the gold standard.
Positive predictive value (PPV), negative predictive value (NPV) in pneumonia patients	2021.01-2024.12	Positive predictive value: the proportion of positive diagnostic test results to be evaluated that are actually diseased, i.e., the percentage of positive results that are predictive of actual disease.; Negative predictive value: the proportion of cases that are positive for a given disease among the diagnostic tests to be evaluated, i.e., the percentage of cases that can be predicted to be truly diseased from the positive results.

Secondary Outcome Measures

Name	Time	Method
Therapeutic success rate	2021.01-2024.12	Therapeutic success rate: the proportion of cases in which the diagnostic test to be evaluated was positive that were successfully treated.
the proportion of cases in which an adverse event occurs.	2021.01-2024.12	Safety: the proportion of cases in which an adverse event occurs.
the average length of stay of patients in the hospital.	2021.01-2024.12	Mean length of stay: the average length of stay of patients in the hospital.
Survival rate	2021.01-2024.12	Survival rate: the proportion of treated patients who are alive at 30, 60 and 90 days after the onset of illness.

Trial Locations

Locations (1)

Guangdong Locations; 🇨🇳 Guangzhou, Guangdong, China